Edward Motea, PhD
Education: Gannon University, B.S. in Chemistry, magna cum laude, 2006. Case Western Reserve University, Ph.D. in Chemistry (Cancer Pharmacology
Training Program) under the mentorship of Dr. Anthony Berdis and Dr. Irene Lee, 2012.
During the course of Edward’s graduate work, he became very
interested in the mechanism of drug resistance and/or carcinogesis induced by endogenous and exogenous DNA-damaging agents. His doctoral work
was focused on understanding the chemistry and enzymology of translesion DNA synthesis (TLS), or the replication of damaged DNA (particularly
noninstructional or nontemplated DNA lesions), using rationally designed non-natural nucleotides as biochemical probes. The mechanistic insights
gained from this work has led to the development of a novel chemical agent with combined therapeutic and diagnostic (theranostic) potentials –
an innovative strategy for improving the treatment of cancer patients. Currently, he is investigating the biological function(s) of Kub5/Hera and a
close homolog in DSB repair and genomic instability. Critical insights into the mechanism(s) by which cancer cells repair and survive the deleterious
effects of genomic lesions caused by DNA-damaging agents could lead to the development of novel therapeutics and innovative strategies for
personalized cancer therapy.